Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Kindeva Drug Delivery Receives £33M U.K. Government Grant | Contract Pharma

What are you searching for?

Sign in
Breaking News

Kindeva Drug Delivery Receives £33M U.K. Government Grant

Supports global development and manufacturing of the next generation of green pressurized metered-dose inhalers.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Kindeva Drug Delivery, a global drug delivery device CDMO, received a £33 million grant from the U.K. Government’s Life Sciences Innovation Manufacturing Fund (LSIMF) toward enhancing inhaler manufacturing and sustainability. The joint funds aim to enhance Kindeva’s capability and capacity to manufacture the next generation of green pressurized metered-dose inhalers (pMDIs) and to continue delivering evolving therapies for respiratory diseases.

The investment supports global development and manufacturing of inhalers using new, lower global warming potential (GWP) propellants, while creating local jobs across the company’s two U.K. sites — Loughborough and Clitheroe.

Additionally, this industry and government investment supports green improvements to Kindeva’s underlying inhaler componentry supply chain at the company’s Clitheroe site.

“This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the U.K., as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products,” said Kindeva global chief commercial officer David Stevens. “This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics